Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Colorectal cancer (CRC) remains a formidable health burden worldwide, with up to 50% of
patients developing metastases during the course of their disease. This group of CRC …

Antibody combinations targeting cell surface receptors are a new modality of cancer therapy.
The trafficking and signalling mechanisms regulated by such therapeutics are not fully …

Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Background Gastric and esophageal adenocarcinomas are major global cancer burdens.
These cancer forms are characterized by a poor prognosis and a modest response to chemo …

Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …

Background Human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric
and gastroesophageal adenocarcinoma (GEA) is globally treated with chemotherapy plus …

Background Gastroesophageal cancers are often grouped together even though cancers
that originate in the esophagus often exhibit different histological features, geographical …

Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are effective
cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally …

Over 90% of head and neck cancers overexpress the epidermal growth factor receptor
(EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer …